Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

Dicerna Phar Form 4 January 12, 2	maceuticals Inc										
								-	OMB APPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE C Washington, D.C. 20549						COMMISSION	N OMB Number:	3235-	0287		
Check this box Januar								ry 31, 2005 0.5			
(Print or Type R	lesponses)										
Bhargava Pankaj Symbo Dicer				Issuer Name and Ticker or Trading bol cerna Pharmaceuticals Inc RNA]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Mc				3. Date of Earliest Transaction (Month/Day/Year) 01/08/2016				Director 10% Owner X Officer (give title Other (specify below) below) Chief Medical Officer			
				Amendment, Date Original Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Secur	ities A	cquired, Disposed (of, or Beneficia	lly Owne	d
Security ((Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any (Month/Da	ed Date, if ay/Year)	3. Transactio Code (Instr. 8) Code V	4. Securit nAcquired Disposed (Instr. 3, -	ies (A) or of (D) 4 and 5 (A) or (D)	5) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature Indirect	e of al ip
Reminder: Repo	ort on a separate line	e for each cl	ass of sec	urities benef	ficially ow	ned dir	rectly o	r indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 9.09	01/08/2016		A	75,000	<u>(1)</u>	01/08/2026	Common Stock	75,000

Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			
Bhargava Pankaj C/O DICERNA PHARMACEUTICALS, 87 CAMBRIDGEPARK DRIVE CAMBRIDGE, MA 02140	INC.		Chief Medical Officer				
Signatures							
/s/ Michael Todisco, attorney-in-fact	01/12/2016						

01/12/2016

**Signature of Reporting Person

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option vests in 48 monthly installments over the four-year period with a vesting start date of January 8, 2016, subject in each case to (1) the reporting person's continued employment with the issuer through the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.